PT - JOURNAL ARTICLE AU - Ferreira, Leonardo Souto AU - Canton, Otavio AU - Paixão da Silva, Rafael Lopes AU - Poloni, Silas AU - Sudbrack, Vítor AU - Borges, Marcelo Eduardo AU - Franco, Caroline AU - Darcie Marquitti, Flávia Maria AU - de Moraes, José Cássio AU - de Sousa Mascena Veras, Maria Amélia AU - André Kraenkel, Roberto AU - Coutinho, Renato Mendes TI - Assessing optimal time between doses in two-dose vaccination regimen in an ongoing epidemic of SARS-CoV-2 AID - 10.1101/2021.07.28.21261200 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.28.21261200 4099 - http://medrxiv.org/content/early/2021/07/31/2021.07.28.21261200.short 4100 - http://medrxiv.org/content/early/2021/07/31/2021.07.28.21261200.full AB - The SARS-CoV-2 pandemic is a major concern all over the world and, as vaccines became available at the end of 2020, optimal vaccination strategies were subjected to intense investigation. Considering their critical role in reducing disease burden, the increasing demand outpacing production, and that most currently approved vaccines follow a two-dose regimen, the cost-effectiveness of delaying the second dose to increment the coverage of the population receiving the first dose is often debated. Finding the best solution is complex due to the trade-off between vaccinating more people with lower level of protection and guaranteeing higher protection to a fewer number of individuals.Here we present a novel extended age-structured SEIR mathematical model that includes a two-dose vaccination schedule with a between-doses delay modelled through delay differential equations and linear optimization of vaccination rates. Simulations for each time window and for different types of vaccines and production rates were run to find the optimal time window between doses, that is, the one that minimizes the number of deaths.We found that the best strategy depends on an interplay between the vaccine production rate and the relative efficacy of the first dose. In the scenario of low first-dose efficacy, it is always better to apply the second dose as soon as possible, while for high first-dose efficacy, the optimal window depends on the production rate and also on second-dose efficacy provided by each type of vaccine. We also found that the rate of spread of the infection does not affect significantly the thresholds of the optimal window, but is an important factor in the absolute number of total deaths. These conclusions point to the need to carefully take into account both vaccine characteristics and roll-out speed to optimize the outcome of vaccination strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil (Finance Code 001 to LSF and FMDM), Conselho Nacional de Desenvolvimento Científico e Tecnoló;gico, Brazil (grant number: 315854/2020-0 to MEB, 141698/2018-7 to RLPS, 312559/2020-8 to MASMV and 311832/2017-2 to RAK), Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil (grant number: 2019/26310-2 and 2017/26770-8 to CF, 2018/26512-1 to OC, 2018/24037-4 to SPL and contract number: 2016/01343-7 to RAK) and Swiss National Science Foundation (grant PCEFP3_181243 to VS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was not necessary because this study analysed only publicly available data, not including identifiable information.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe algorithm developed in this work is available in our GitHub Repository. https://github.com/covid19br/VaxModel-paper